ABBOTT LABORATORIES (ABT) Stock Analyst Ratings
USA - New York Stock Exchange - NYSE:ABT - US0028241000 - Common Stock
126.45 USD
+2.26 (+1.82%)
126.343 USD
-0.11 (-0.08%)
ChartMill assigns a Buy % Consensus number of 79% to ABT. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 146.81. This target is 16.1% above the current price.
ABT was analyzed by 35 analysts. The buy percentage consensus is at 79. So analysts seem to be have mildly positive about ABT.
In the previous month the buy percentage consensus was at a similar level.
ABT was analyzed by 35 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2026-01-05 | Barclays | Maintains | Overweight -> Overweight |
| 2025-11-20 | BTIG | Reiterate | Buy -> Buy |
| 2025-10-17 | Barclays | Maintains | Overweight -> Overweight |
| 2025-10-16 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-10-16 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-10-16 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-10-16 | Raymond James | Maintains | Outperform -> Outperform |
| 2025-10-15 | BTIG | Reiterate | Buy -> Buy |
| 2025-10-10 | Benchmark | Initiate | Buy |
| 2025-10-07 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-07-18 | Mizuho | Maintains | Neutral -> Neutral |
| 2025-07-18 | BTIG | Maintains | Buy -> Buy |
| 2025-07-18 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-07-18 | Raymond James | Maintains | Outperform -> Outperform |
| 2025-07-18 | Jefferies | Upgrade | Hold -> Buy |
| 2025-07-16 | Mizuho | Maintains | Neutral -> Neutral |
| 2025-07-15 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-07-15 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-07-08 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-04-17 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-04-17 | Stifel | Maintains | Buy -> Buy |
| 2025-04-17 | Barclays | Maintains | Overweight -> Overweight |
| 2025-04-17 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-04-17 | Raymond James | Maintains | Outperform -> Outperform |
| 2025-04-17 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-04-17 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2025-04-17 | Jefferies | Maintains | Hold -> Hold |
| 2025-03-10 | B of A Securities | Maintains | Buy -> Buy |
| 2025-03-04 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-03-04 | Citigroup | Maintains | Buy -> Buy |
ABBOTT LABORATORIES / ABT FAQ
Can you provide the average price target for ABBOTT LABORATORIES stock?
35 analysts have analysed ABT and the average price target is 146.81 USD. This implies a price increase of 16.1% is expected in the next year compared to the current price of 126.45.
What is the consensus rating for ABT stock?
The consensus rating for ABBOTT LABORATORIES (ABT) is 79.4286 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover ABBOTT LABORATORIES (ABT) stock?
The number of analysts covering ABBOTT LABORATORIES (ABT) is 35.